Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Med
Main Authors: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Hackl, Hubert, Steiner, Markus, Monzo-Fuentes, Claudia, Melchardt, Thomas, Magnes, Teresa, Huemer, Florian, Westphal, Theresa, Hufnagl, Clemens, Hauser-Kronberger, Cornelia, Egle, Alexander, Greil, Richard
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7355487/
https://ncbi.nlm.nih.gov/pubmed/32492882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061663
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki